Clinical Trials Logo

Clinical Trial Summary

This study evaluates the efficacy of erythropoietin in refractory autoimmune encephalitis. Ten patients will receive 100 IU/kg of erythropoietin 3 times a week for 12 weeks.

Clinical Trial Description

Erythropoietin can improve the refractory autoimmune encephalitis. Erythropoietin has tissue-protective effect via activation of Janus kinase (JAK)-2, signal transducer and activator of transcription (STAT)-5 pathway and NF-kappa B pathway. The activation of JAK-2 and STAT-5 promote hemoglobin synthesis and facilitate cell cycle progression. Also, NF-kappa B pathway inhibition regulates pro-inflammatory cytokine production.

We expect that erythropoietin may lead to improve the symptoms and outcome of autoimmune encephalitis. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

NCT number NCT03004209
Study type Interventional
Source Seoul National University Hospital
Contact Keun Tae Kim, M.S
Phone +82-2-2072-3192
Email [email protected]
Status Recruiting
Phase Phase 4
Start date December 2016

See also
  Status Clinical Trial Phase
Recruiting NCT04708626 - Cumulative Incidence of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
Not yet recruiting NCT04106596 - HLA Analysis in Autoimmune Encephalitis and Related Disorders
Completed NCT04175522 - Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: Phase 2
Recruiting NCT03194815 - IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 Phase 2
Not yet recruiting NCT03957616 - Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
Completed NCT02905136 - Mechanisms of Auto-immune Encephalitis
Recruiting NCT03993262 - Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis Phase 2
Recruiting NCT03872284 - Neuro-ophthalmology and Autoimmune Encephalitis (NODE)
Completed NCT03835728 - Efficacy of Ocrelizumab in Autoimmune Encephalitis Phase 2
Not yet recruiting NCT04372615 - The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis Phase 2
Recruiting NCT04823728 - HLA Analysis in Autoimmune Encephalitis and Related Disorders: Part II
Recruiting NCT03542279 - Immunotherapy in Autoimmune Encephalitis N/A
Completed NCT03530462 - To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI
Recruiting NCT04339127 - Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis